IBDEI1Z3 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,751,0)
 ;;=MENTAL DISORDERS^6^69
 ;;^UTILITY(U,$J,358.4,752,0)
 ;;=MUSCULOSKELETAL/CONNECTIVE TISSUE^7^69
 ;;^UTILITY(U,$J,358.4,753,0)
 ;;=TERTIARY DX-TBI CODES^10^69
 ;;^UTILITY(U,$J,358.4,754,0)
 ;;=QUATERNARY DX-POLYTRAUMA/TBI V-CODE^9^69
 ;;^UTILITY(U,$J,358.4,755,0)
 ;;=PHYSICAL^8^69
 ;;^UTILITY(U,$J,358.4,756,0)
 ;;=ANEMIA^1^70
 ;;^UTILITY(U,$J,358.4,757,0)
 ;;=COAGULATION DISORDERS^4^70
 ;;^UTILITY(U,$J,358.4,758,0)
 ;;=MYELOID NEOPLASMS & DISORDERS^13^70
 ;;^UTILITY(U,$J,358.4,759,0)
 ;;=LYMPHOID NEOPLASMS^10^70
 ;;^UTILITY(U,$J,358.4,760,0)
 ;;=GI CANCER^7^70
 ;;^UTILITY(U,$J,358.4,761,0)
 ;;=HEAD, NECK & LUNG NEOPLASMS^8^70
 ;;^UTILITY(U,$J,358.4,762,0)
 ;;=MISC. NEOPLASMS^12^70
 ;;^UTILITY(U,$J,358.4,763,0)
 ;;=METASTATIC SITES^11^70
 ;;^UTILITY(U,$J,358.4,764,0)
 ;;=COUNSELING & SCREENING^5^70
 ;;^UTILITY(U,$J,358.4,765,0)
 ;;=HEMOGLOBINOPATHIES^9^70
 ;;^UTILITY(U,$J,358.4,766,0)
 ;;=GENITOURINARY NEOPLASMS^6^70
 ;;^UTILITY(U,$J,358.4,767,0)
 ;;=BREAST & GYN NEOPLASMS^3^70
 ;;^UTILITY(U,$J,358.4,768,0)
 ;;=ARTIFICIAL OPENING STATUS^2^70
 ;;^UTILITY(U,$J,358.4,769,0)
 ;;=PERSONAL HX OF CANCER^14^70
 ;;^UTILITY(U,$J,358.4,770,0)
 ;;=SPECIAL SERVICES^7^71
 ;;^UTILITY(U,$J,358.4,771,0)
 ;;=TREATMENT^8^71
 ;;^UTILITY(U,$J,358.4,772,0)
 ;;=MISCELLANEOUS^5^71
 ;;^UTILITY(U,$J,358.4,773,0)
 ;;=IMMUNIZATIONS^3^71
 ;;^UTILITY(U,$J,358.4,774,0)
 ;;=CHEMO ADMINISTRATION^1^71
 ;;^UTILITY(U,$J,358.4,775,0)
 ;;=CHEMO DRUGS^2^71
 ;;^UTILITY(U,$J,358.4,776,0)
 ;;=OTHER DRUGS^6^71
 ;;^UTILITY(U,$J,358.4,777,0)
 ;;=MGMT L/T ANTICOAG TX^4^71
 ;;^UTILITY(U,$J,358.4,778,0)
 ;;=NEW PATIENT^2^72
 ;;^UTILITY(U,$J,358.4,779,0)
 ;;=ESTABLISHED PATIENT^1^72
 ;;^UTILITY(U,$J,358.4,780,0)
 ;;=CONSULTATIONS^3^72
 ;;^UTILITY(U,$J,358.4,781,0)
 ;;=POST OP^4^72
 ;;^UTILITY(U,$J,358.4,782,0)
 ;;=HOSPICE CARE SUPERVISION^1^73
 ;;^UTILITY(U,$J,358.4,783,0)
 ;;=PROLONGED SERVICES^2^73
 ;;^UTILITY(U,$J,358.4,784,0)
 ;;=INPATIENT CONSULTATIONS^1^74
 ;;^UTILITY(U,$J,358.4,785,0)
 ;;=INITIAL INPATIENT CARE^2^74
 ;;^UTILITY(U,$J,358.4,786,0)
 ;;=SUBSEQUENT INPATIENT CARE^3^74
 ;;^UTILITY(U,$J,358.4,787,0)
 ;;=DISCHARGE/PRONOUNCEMENT^4^74
 ;;^UTILITY(U,$J,358.4,788,0)
 ;;=NURSING HOME INITIAL INPATIENT CARE^5^74
 ;;^UTILITY(U,$J,358.4,789,0)
 ;;=NURSING HOME SUBSEQUENT INPATIENT CARE^6^74
 ;;^UTILITY(U,$J,358.4,790,0)
 ;;=NURSING HOME DISCHARGE/PRONOUNCEMENT^7^74
 ;;^UTILITY(U,$J,358.4,791,0)
 ;;=CANCER & HEMATOLOGIC CONDITIONS^2^75
 ;;^UTILITY(U,$J,358.4,792,0)
 ;;=PALLIATIVE/HOSPICE ENCOUNTER^1^75
 ;;^UTILITY(U,$J,358.4,793,0)
 ;;=CNS CONDITIONS OTHER THAN CANCER^4^75
 ;;^UTILITY(U,$J,358.4,794,0)
 ;;=CARDIOPULMONARY COND OTHER THAN CANCER^3^75
 ;;^UTILITY(U,$J,358.4,795,0)
 ;;=GASTROINTESTINAL COND OTHER THAN CANCER^6^75
 ;;^UTILITY(U,$J,358.4,796,0)
 ;;=RENAL COND OTHER THAN CANCER^9^75
 ;;^UTILITY(U,$J,358.4,797,0)
 ;;=DERMATOLOGIC CONDITIONS^5^75
 ;;^UTILITY(U,$J,358.4,798,0)
 ;;=RHEUMATOLOGIC/VASCULITIC/THROMBOEMBOLIC^10^75
 ;;^UTILITY(U,$J,358.4,799,0)
 ;;=INFECTIOUS CONDITIONS & SIRS^7^75
 ;;^UTILITY(U,$J,358.4,800,0)
 ;;=NON-VIDEO MONITORING^8^75
 ;;^UTILITY(U,$J,358.4,801,0)
 ;;=HOSPICE CARE SUPERVISION^3^76
 ;;^UTILITY(U,$J,358.4,802,0)
 ;;=ADVANCE LIFE PLANNING^1^76
 ;;^UTILITY(U,$J,358.4,803,0)
 ;;=EDUCATION^2^76
 ;;^UTILITY(U,$J,358.4,804,0)
 ;;=NON-VIDEO MONITORING^4^76
 ;;^UTILITY(U,$J,358.4,805,0)
 ;;=TEAM CONFERENCE^6^76
 ;;^UTILITY(U,$J,358.4,806,0)
 ;;=PROLONGED SERVICES^5^76
 ;;^UTILITY(U,$J,358.4,807,0)
 ;;=NEW PATIENT ^2^77
 ;;^UTILITY(U,$J,358.4,808,0)
 ;;=ESTABLISHED PATIENT ^1^77
